ArticleEuropean journal of nuclear medicine and molecular imaging2026

Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN).

Thomas Büttner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.